Baidu
map

Eur Heart J:他汀类药物可预防静脉血栓

2017-03-29 MedSci MedSci原创

莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类药物可以“显著降低”身体某些部位血液凝固的发生。

莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类药物可以"显着降低"身体某些部位凝血的发生。

研究团队对几项降低胆固醇的药物研究进行了分析,发现该类药可能在降低静脉血栓栓塞(VTE)的复发风险中起潜在作用。

该研究获得东米德兰健康应用研究与护理中心的NIHR项目的资助,结果发表在《European Heart Journal》上。

最新研究结果与同组1月发表的研究报告类似,该研究小组建议他汀类药物能将病情的威胁降低15%至25%。

谈到最新的研究,该研究参与人,莱斯特大学初级保健糖尿病与血管医学教授,NIHR CLAHRC East Midlands院长,莱斯特糖尿病中心联合主任Kamlesh Khunti教授说,"曾经有迹象表明他汀类药物可能在预防VTE方面发挥潜在作用,但证据不足。"

"我们想进一步探讨这个问题,将所有研究结合起来,以评估他汀类药物与复发性VTE之间的关系。尽可能多的了解这种情况对我们来说很重要,因为据说世界上每6秒就会有一个人死于VTE。"

"尽管严重,但是只要得到正确的照顾,绝大多数血块是可以完全避免的。然而,治疗为英国的卫生服务带来相当大的经济负担,因为它被认为需花费大约6.4亿英镑来管理病情。"

在此过程中,对基于他汀类药物和VTE 的8项研究进行了汇总分析,其中涉及到103,500多名参与者。

来自布里斯托尔大学临床科学学院肌肉骨骼研究组的首席研究员Setor Kunutsor博士说:"虽然我们的研究还没有发现VTE的原因,但是在处理这种病症时,利用他汀类药物治疗确实具有潜在作用。"

"我们的研究显示,大量的证据表明,他汀类药物可能在VTE的一级和二级预防中起着潜在的作用。"

希望这一发现可以产生新的指导方针和扩大其在心血管疾病预防中的使用。

原文出处

Setor K. Kunutsor et.al.Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.Eur Heart J 2017 ehx107. doi: 10.1093/eurheartj/ehx107

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955273, encodeId=b09a19552e32a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 06 04:10:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044443, encodeId=b51e2044443d6, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Sep 06 07:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697431, encodeId=8ea8169e4312c, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Jun 28 05:10:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356205, encodeId=4898135620512, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562468, encodeId=0759156246817, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2018-03-06 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955273, encodeId=b09a19552e32a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 06 04:10:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044443, encodeId=b51e2044443d6, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Sep 06 07:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697431, encodeId=8ea8169e4312c, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Jun 28 05:10:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356205, encodeId=4898135620512, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562468, encodeId=0759156246817, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955273, encodeId=b09a19552e32a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 06 04:10:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044443, encodeId=b51e2044443d6, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Sep 06 07:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697431, encodeId=8ea8169e4312c, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Jun 28 05:10:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356205, encodeId=4898135620512, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562468, encodeId=0759156246817, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-06-28 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955273, encodeId=b09a19552e32a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 06 04:10:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044443, encodeId=b51e2044443d6, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Sep 06 07:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697431, encodeId=8ea8169e4312c, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Jun 28 05:10:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356205, encodeId=4898135620512, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562468, encodeId=0759156246817, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-03-31 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955273, encodeId=b09a19552e32a, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 06 04:10:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044443, encodeId=b51e2044443d6, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Sep 06 07:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697431, encodeId=8ea8169e4312c, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Jun 28 05:10:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356205, encodeId=4898135620512, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562468, encodeId=0759156246817, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 31 12:10:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
    2017-03-31 slcumt

相关资讯

Chest:他汀类药物对COPD患者有明显获益

该研究结果表明,在COPD患者人群中使用他汀类药物就肺相关死亡率和全因死亡率降低而言可能带来的临床益处。

收藏!他汀类药物研究进展

他汀类药物是一种在临床上使用非常广泛的降脂药物,他汀类药物可抑制肝脏合成载脂蛋白B-100,从而减少富含甘油三酯AV、脂蛋白的合成和分泌,同时大量研究也都已经证实,他汀类药物可降低冠心病的发病率和死亡率,减缓动脉粥样硬化斑块的发展,甚至使斑块消退,从而打破了冠心病不可逆转的传统观念。本文中小编盘点了他汀类药物近期的相关研究进展,与各位一起学习!【1】Chest:他汀类药物对COPD患者有明显获

Eur Heart J:他汀类药物与静脉血栓栓塞的二级预防效果如何?

由此可见,观察性队列研究的证据显示他汀类药物对复发性VTE有益。需要精心设计的干预研究来证实这些发现。

老年他汀类药物治疗肌酶异常病例的诊治思路

他汀类药物广泛用于心血管疾病的防治,肌肉损害是部分患者不耐受他汀类药物的重要原因。老年患者因他汀类药物导致的肌肉症状(肌肉酸痛、疼痛或无力)发生率较高。马萨诸塞州东部一项回顾性队列研究显示,107835例接受他汀类药物治疗的患者中18778例(17%)出现了与他汀类药物相关的不良事件(40%为肌肉骨骼系统不良事件)。其中,11124例患者停止他汀类药物治疗。在6579例重新启动他汀类药物治疗的患者

近期他汀类药物研究进展解析

他汀类药物是一种在临床上使用非常广泛的降脂药物,随着全球第一个他汀类药物洛伐他汀获美国 FDA 批准上市以来,随后一些新药,比如辛伐他汀、阿伐他汀等他汀类新药也不断问世,同时大量研究也都已经证实,他汀类药物可降低冠心病的发病率和死亡率,减缓动脉粥样硬化斑块的发展,甚至使斑块消退,从而打破了冠心病不可逆转的传统观念。 本文中小编盘点了他汀类药物近期的相关研究进展,与各位一起学习! 【1】

JAMA Neurology:他汀类药物预防阿尔兹海默病?服用2年降低15%的患病率

导读 他汀类药物能够预防阿尔兹海默症?近期,《JAMA Neurology》期刊最新刊出一篇学术文章揭示,他汀类药物能够对大脑产生积极的影响,连续服用2年能够显著降低老年人患老年痴呆症的概率。

Baidu
map
Baidu
map
Baidu
map